Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Jan;32(1):24-26.
doi: 10.1245/s10434-024-16335-0. Epub 2024 Oct 7.

Recognizing the Role for Conversion Therapy in Metastatic Esophageal Squamous Cell Cancer (ESCC): A Call for Future Study

Alison S Baskin  1 , Jeffrey B Velotta  2   3
Affiliations
Editorial

Recognizing the Role for Conversion Therapy in Metastatic Esophageal Squamous Cell Cancer (ESCC): A Call for Future Study

Alison S Baskin et al. Ann Surg Oncol. 2025 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosure: There authors have no conflicts of interest or funding relevant to this manuscript.

References

    1. Pape M, Vissers PA, de Vos-Geelen J, Hulshof MC, Gisbertz SS, Jeene PM, et al. Treatment patterns and survival in advanced unresectable esophageal squamous cell cancer: a population-based study. Cancer Sci. 2022;113(3):1038–46. https://doi.org/10.1111/cas.15262 . - DOI - PubMed - PMC
    1. Then EO, Lopez M, Saleem S, Gayam V, Sunkara T, Culliford A, et al. Esophageal cancer: an updated surveillance epidemiology and end results database analysis. World J Oncol. 2020;11(2):55. https://doi.org/10.14740/wjon1254 . - DOI - PubMed - PMC
    1. Chan WL, Choi CW, Wong IY, Tsang TH, Lam AT, Tse RP, et al. Docetaxel, cisplatin, and 5-FU triplet therapy as conversion therapy for locoregionally advanced unresectable esophageal squamous cell carcinoma. Ann Surg Oncol. 2023;30(2):861–70. https://doi.org/10.1245/s10434-022-12694-8 . - DOI - PubMed
    1. Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759–71. https://doi.org/10.1016/S0140-6736(21)01234-4 . - DOI - PubMed
    1. Matsuda S, Tsushima T, Kato K, Hsu CH, Lee JM, Wong IY, et al. Defining conversion therapy for esophageal squamous cell carcinoma. Ann Gastroenterol Surg. 2023;7(1):7. https://doi.org/10.1002/ags3.12623 . - DOI - PubMed

Publication types

LinkOut - more resources